Moracin M |
| カタログ番号GC39539 |
Morus alba L.の皮に含まれるフェノール成分、モラシンM。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 56317-21-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Moracin M is a phosphodiesterase 4 (PDE4) inhibitor (PDE4D2: IC50 = 2.9μM; PDE4B2: IC50 = 4.5μM; PDE5A1: IC50 > 40μM; PDE9A2: IC50 > 100μM) [1]. Moracin M inhibits inflammatory signaling pathways such as NF-κB and MAPK, reducing the production of pro-inflammatory cytokines (such as TNF-α, IL-6, and NO) [2-3]. Moracin M is often used in inflammation research [4].
In human umbilical vein endothelial cells (HUVECs), Moracin M (6.25-25µg/mL;24h) enhances HUVEC tube formation in a dose-dependent manner [5]. In C2C12 cells, Moracin M (25 μM; 48 h) treatment significantly increased myoblast proliferation [6].
In acute lung injury mice model, Moracin M (20mg/kg, 60mg/kg; ig; single administration) inhibits airway inflammation [7]. In LPS-induced mouse airway inflammation model, Moracin M (30mg/kg; po; single administration) effectively reduces airway inflammation in vivo [8].
References:
[1]. Chen S K, Zhao P, Shao Y X, et al. Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor[J]. Bioorganic & medicinal chemistry letters, 2012, 22(9): 3261-3264.
[2]. Yao X, Wu D, Dong N, et al. Moracin C, a phenolic compound isolated from Artocarpus heterophyllus, suppresses lipopolysaccharide-activated inflammatory responses in murine raw264. 7 macrophages[J]. International Journal of Molecular Sciences, 2016, 17(8): 1199.
[3]. Chen L, Wu D, Wang S, et al. Moracin M derivative targeting PDE4 for the treatment of psoriasis[J]. Acta Materia Medica, 2025, 4(2): 293-301.
[4]. Guo F, Zou Y, Zheng Y. Moracin M inhibits lipopolysaccharide-induced inflammatory responses in nucleus pulposus cells via regulating PI3K/Akt/mTOR phosphorylation[J]. International immunopharmacology, 2018, 58: 80-86.
[5]. Chang B Y, Hwang Y, Kim I, et al. The Role of Moracin M in Promoting Hair Growth: Insights into Mechanisms of WNT/β-Catenin Pathway Activation and Angiogenesis Enhancement in Human Dermal Papilla Cells[J]. 2024.
[6]. Kwak H J, Kim J, Kim S Y, et al. Moracin E and M isolated from Morus alba Linné induced the skeletal muscle cell proliferation via PI3K-Akt-mTOR signaling pathway[J]. Scientific reports, 2023, 13(1): 20570.
[7]. Lee J H, Ko H J, Woo E R, et al. Moracin M inhibits airway inflammation by interrupting the JNK/c-Jun and NF-κB pathways in vitro and in vivo[J]. European journal of pharmacology, 2016, 783: 64-72.
[8]. Lee J, Mandava S, Ahn S H, et al. Potential moracin M prodrugs strongly attenuate airway inflammation in vivo[J]. Biomolecules & Therapeutics, 2020, 28(4): 344.
| Cell experiment [1]: | |
Cell lines | Human umbilical vein endothelial cells (HUVECs) |
Preparation Method | The cell migration capacity was evaluated using a scratch wound-healing assay. A synthetic wound was generated in an 80–90% confluent monolayer of HUVECs cultured in a 24-well plate, employing a 200µL pipette tip. The impact of co-culturing HUVECs with Moracin M at concentrations of 6.25, 12.5, and 25µg/mL on cell migration was observed using microscopy at the 0 and 24-hour marks. |
Reaction Conditions | 6.25-25µg/mL;24h |
Applications | Moracin M enhances HUVEC tube formation in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Acute lung injury mice model |
Preparation Method | To establish an animal model of acute lung injury (ALI), a modified ALI model was used. Mice were divided into five groups (n = 13): control, LPS, LPS/Moracin M (20mg/kg and 60mg/kg), and LPS/dexamethasone (30mg/kg). The test compound, containing a reference drug, was dissolved in 0.3% sodium carboxymethylcellulose (CMC) solution and administered orally. The control and LPS groups were also given an equal volume of CMC solution. One hour later, LPS (2mg/kg in PBS) was administered intranasally to the mice (10μL/mouse, five times, for a total of 50μL) to induce bronchitis. Sixteen hours after LPS treatment, the mice (n = 7) were sacrificed, and bronchoalveolar lavage (BAL) fluid was collected via endotracheal cannulation. 700μL of PBS was then infused three times. Approximately 2,000μL of BAL fluid was collected per mouse. The total number of cells in BAL fluid was counted using a hemocytometer, and differential cell counts were performed using a fluorescence-activated cell sorter (FACS). For histological and biochemical analyses, mice (n = 3) were sacrificed, and lung tissue was excised. Histological specimens were fixed and prepared for hematoxylin and eosin (H&E) staining. |
Dosage form | 20mg/kg, 60mg/kg; ig; single administration |
Applications | Moracin M inhibits airway inflammation. |
References: | |
| Cas No. | 56317-21-6 | SDF | |
| Canonical SMILES | OC1=CC(C2=CC3=CC=C(O)C=C3O2)=CC(O)=C1 | ||
| Formula | C14H10O4 | M.Wt | 242.23 |
| 溶解度 | DMSO: 16.67 mg/mL (68.82 mM) | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.1283 mL | 20.6415 mL | 41.2831 mL |
| 5 mM | 825.7 μL | 4.1283 mL | 8.2566 mL |
| 10 mM | 412.8 μL | 2.0642 mL | 4.1283 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *